Patent Cliff

Lipitor expiry leads to 15% dip in Pfizer's US first-quarter sales

Deborah Weinstein May 01, 2012

Pfizer's first-quarter earnings call on Tuesday was as much about the nutrition business sell-off as it was about falling numbers.

Branded drug spend up, but slower growth ahead

Marc Iskowitz April 05, 2012

Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.

Generics makers approach a cliff of their own

Matthew Arnold January 30, 2012

Generic drug sales will peak this year, says a Goldman Sachs report, as the sector approaches its own cliff.

Novartis slashes 1,960 US sales and marketing jobs amid hypertension franchise implosion

Matthew Arnold January 13, 2012

Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.